Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

NCT05046080 — Recruiting, 70 participants, M.D. Anderson Cancer Center

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix - a Rare Tumor

Registry	NCT05046080
Status	Recruiting
Study type	Observational
Enrollment	70 (Estimated)
Sponsor	M.D. Anderson Cancer Center (Other)
Conditions	Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
Interventions	Electronic Health Record Review, Laboratory Biomarker Analysis (Other)
Dates	start 2021-08-06, primary completion 2026-09-29 (estimated), completion 2026-09-29 (estimated), first posted 2021-09-16, last updated 2026-08-10
Locations	1 site in United States

-Summary

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.

Expand all sections · Collapse all

+Detailed description

PRIMARY OBJECTIVE:

I. To perform a retrospective clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix at M D Anderson Cancer Center (MDACC) and to delineate the immunohistochemical and molecular profile of these cases.

OUTLINE:

Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.

+Arms and interventions

Arm	Type	Interventions	Description
Observational (medical record review)		Other: Electronic Health Record Review; Other: Laboratory Biomarker Analysis	Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.

Electronic Health Record Review (Other): Medical records reviewed
Laboratory Biomarker Analysis (Other): Correlative studies

+Outcome measures

Primary outcomes

Clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix [through study completion, an average of 1 year]

+Eligibility

Sex: Female

Inclusion Criteria:

* Patients diagnosed with clear cell carcinoma of the cervix at MDACC

+Locations (1)

Facility	City	Country	Status
M D Anderson Cancer Center	Houston, Texas	United States	Recruiting

+Investigators

Anasis Malpica, Principal investigator, M.D. Anderson Cancer Center